Teva Pharmaceutical Industries (NYSE:TEVA) Given New $27.00 Price Target at UBS Group
Teva Pharmaceutical Industries (NYSE:TEVA – Free Report) had its price target lowered by UBS Group from $30.00 to $27.00 in a research report sent to investors on Thursday,Benzinga reports. The brokerage currently has a buy rating on the stock. Several other research analysts also recently weighed in on TEVA. Barclays dropped their price target on […]
More Stories
DEI Practices Reduce Productivity, Cost $94 Billion Annually: White House Economic Report
By Travis Gillmore WASHINGTON—Diversity, equity, and inclusion practices negatively impacted the U.S. economy, according to the 2026 White House Economic...
Fauci Deputy Who Declined COVID-19 Vaccine Feared Retaliation: Emails
By Zachary Stieber A top government doctor who declined to receive a COVID-19 vaccine in 2021 was worried he would...
20+ SEO Checklist For Blog Posts: Read Before Publishing
You wrote a fantastic blog. What’s next? Publishing blogs without optimizing them for SEO is like starting a shop without...
US Military Blockade on Iranian Ports Goes Into Effect, Maritime Group Says
By Jack Phillips A scheduled U.S. naval blockade of the Strait of Hormuz and nearby waters started at 10 a.m....
Who is Jonathan Joly? Age, Marriage, and Net Worth in 2026
If you like to scroll on social media, the chances of you witnessing Jonathan Joly are high. Are you also...
Rory McIlroy Wins Back-to-Back Masters Titles to Join Jack Nicklaus, Nick Faldo, and Tiger Woods
By The Associated Press AUGUSTA, Ga.—Rory McIlroy joined more elite company Sunday at the Masters when he pulled away with...